In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide ACTH (corticotropin) | Natural peptide Oxytocin | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Natural peptide | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 181 | 3,492 (plus 1,148 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 22 (20 in people) | 157 (152 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 102 · 7 active199 more mention it but do not test it | 690 · 65 active238 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Acthar Gel says: “Infantile spasms, acute exacerbations of multiple sclerosis, and specified inflammatory and edematous disorders, subject to label conditions”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | ACTH (corticotropin) | Oxytocin |
|---|---|---|
| Cognition and memoryNervous system and cognition | 11 | 41440311 |
| Anxiety and moodMental health and mood |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Pitocin says: “Antepartum: medically indicated induction of labor, stimulation or reinforcement of labor, adjunctive therapy in incomplete or inevitable abortion” No central EU authorisation (EMA).
211
34132417 |
| Adverse eventsWhole body | 20182 | 1261233 |
|---|
| Receptor activity and mechanismNervous system and cognition | 29920 | 28960801472 |
|---|
| PainImmune and inflammation | 11 | 1098524 |
|---|
| PharmacokineticsPharmacology | 422 | 9168203 |
|---|
| Sexual functionReproductive and sexual health | 22 | 7647245 |
|---|
| Glycemic controlMetabolic and weight | 11 | 312254 |
|---|
| Kidney functionKidney and urinary | 1082 | 42735 |
|---|
| Immune responseKidney and urinary | 24177 | 321 |
|---|
| Inflammation markersImmune and inflammation | 927 | 3210166 |
|---|
| Exercise and physical functionNervous system and cognition | 22 | 1717 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | ACTH (corticotropin) | Oxytocin |
|---|---|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size | No comparable result 2 randomized-trial results measure it in another way or another unit. | −1.12 effect size Effect size Dose studied: 48 IU/day6 weeksn = 1032020 |
| Anxiety and moodMental health and moodCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −20% Score reduction · Shown as a change. The study reports a score reduction of this size. Placebo: −4% Dose studied: 20 IU twice daily in week 1, then 40 IU twice daily8 weeksn = 402013 |
| NeuroprotectionNervous system and cognitionCompared as: value in the arm that got the peptide, in µm | −13.1 µm pRNFL loss n = 372023 | No comparable result 4 randomized-trial results measure it in another way or another unit. |
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in days | 23 days Median time to first relapse · ACTH; interquartile range 9-32 Control; interquartile range 14-51: 21 days Dose studied: 80 U/1.73 m² twice weekly6 monthsn = 312018 | |
| Exercise and physical functionNervous system and cognitionCompared as: difference from placebo, in kg | No comparable result 1 randomized-trial result measure it in another way or another unit. | 2.25 kg Whole body lean mass difference Dose studied: 24 IU 4 times per day8 weeksn = 212021 |
| Receptor activity and mechanismPharmacologyCompared as: value in the arm that got the peptide, in proteins | No comparable result 5 randomized-trial results measure it in another way or another unit. | 198 proteins Differentially expressed proteins Dose studied: 24 IUsingle dosen = 192026 |
| PainNervous system and cognitionCompared as: difference from placebo, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −11% allodynic area change Dose studied: 100 µgn = 52023 |
| Sexual functionReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | No randomized trial result 2 results from other study designs. | 26% FSFI score change Placebo: 31% Dose studied: 32 IU8 weeksn = 302015 |
| Cognition and memoryNervous system and cognitionCompared as: difference from placebo, in sd | No randomized trial result 1 result from other study designs. | 1.39 SD effect size n = 262017 |
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in mmol/l × min | No randomized trial result 1 result from other study designs. | 2240 mmol/L × min Glucose AUC Placebo: 2190 mmol/L × min Dose studied: 24 IUn = 252024 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in symptoms per patient | 0 symptoms per patient Psychiatric symptoms per patient 15 monthsn = 232017 |
No comparable result
2 randomized-trial results measure it in another way or another unit.
−1.12 effect size
Effect size
Dose studied: 48 IU/day6 weeksn = 1032020
No comparable result 1 randomized-trial result measure it in another way or another unit. |
No comparable result 66 randomized-trial results measure it in another way or another unit. |
No comparable result
1 randomized-trial result measure it in another way or another unit.
−20%
Score reduction · Shown as a change. The study reports a score reduction of this size.
Placebo: −4%
Dose studied: 20 IU twice daily in week 1, then 40 IU twice daily8 weeksn = 402013
−13.1 µm
pRNFL loss
n = 372023
No comparable result
4 randomized-trial results measure it in another way or another unit.
23 days
Median time to first relapse · ACTH; interquartile range 9-32
Control; interquartile range 14-51: 21 days
Dose studied: 80 U/1.73 m² twice weekly6 monthsn = 312018
No comparable result
1 randomized-trial result measure it in another way or another unit.
No comparable result
1 randomized-trial result measure it in another way or another unit.
2.25 kg
Whole body lean mass difference
Dose studied: 24 IU 4 times per day8 weeksn = 212021
No comparable result
5 randomized-trial results measure it in another way or another unit.
198 proteins
Differentially expressed proteins
Dose studied: 24 IUsingle dosen = 192026
No comparable result
1 randomized-trial result measure it in another way or another unit.
−11%
allodynic area change
Dose studied: 100 µgn = 52023
No randomized trial result
2 results from other study designs.
26%
FSFI score change
Placebo: 31%
Dose studied: 32 IU8 weeksn = 302015
No randomized trial result
1 result from other study designs.
1.39 SD
effect size
n = 262017
No randomized trial result
1 result from other study designs.
2240 mmol/L × min
Glucose AUC
Placebo: 2190 mmol/L × min
Dose studied: 24 IUn = 252024
0 symptoms per patient
Psychiatric symptoms per patient
15 monthsn = 232017
No comparable result
66 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 102 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Mallinckrodt172 participants16 Dec 2016 to 25 Oct 2019
Lupus Erythematosus, Systemic
Mallinckrodt143 participants22 Jun 2017 to 25 Nov 2019
Amyotrophic Lateral Sclerosis
State University of New York at Buffalo64 participantsAug 2013 to 1 Nov 2018
Multiple Sclerosis
199 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010
Uterine Atony · Postpartum Hemorrhage
Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020
Dystocia
University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019
Post Partum Hemorrhage
238 more mention it but do not test it. They only measure it or name it in their text.